Evidence map›Paper›PMID 38259464›Full record

ReviewFrontiers in immunology2023

Lipid peroxidation of immune cells in cancer.

Liuling Xiao, Miao Xian, Chuanchao Zhang, Qi Guo, Qing Yi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Babassu (Foods (Basel, Switzerland) · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Liuling Xiao *Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, United States.
Miao Xian *Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, United States.
Chuanchao ZhangCenter for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, United States.
Qi GuoCenter for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, United States.
Qing YiCenter for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, United States.
Houston Methodist · US

Funding

Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustionR01CA239255 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2019 to 2023
$2.1M
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cellsR01CA282099 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Qing Yi · 2023 to 2026
$1.9M
Role of MIF in myeloma bone homing and drug responseR01CA211073 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2017 to 2021
$1.8M
A novel T-cell subset able to kill relapsed cancersR01CA200539 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2016 to 2020
$1.8M
Targeting macrophages to sensitize myeloma to immune checkpoint blockadeR01CA214811 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2017 to 2021
$1.7M
NCI NIH HHS R01 CA200539NCI NIH HHS R01 CA211073NCI NIH HHS R01 CA214811NCI NIH HHS R01 CA239255NCI NIH HHS R01 CA282099
6 · The paper itself

Abstract

Growing evidence indicates that cellular metabolism is a critical determinant of immune cell viability and function in antitumor immunity and lipid metabolism is important for immune cell activation and adaptation to the tumor microenvironment (TME). Lipid peroxidation is a process in which oxidants attack lipid-containing carbon-carbon double bonds and is an important part of lipid metabolism. In the past decades, studies have shown that lipid peroxidation participates in signal transduction to control cell proliferation, differentiation, and cell death, which is essential for cell function execution and human health. More importantly, recent studies have shown that lipid peroxidation affects immune cell function to modulate tumor immunity and antitumor ability. In this review, we briefly overview the effect of lipid peroxidation on the adaptive and innate immune cell activation and function in TME and discuss the effectiveness and sensitivity of the antitumor ability of immune cells by regulating lipid peroxidation.

Indexed as

NeoplasmsCarbonCell DeathCell DifferentiationHumansLipid PeroxidationTumor MicroenvironmentCarbonadaptive immune cellsinnate immune cellslipid peroxidationTMEtumor immunity

Identifiers

PMID38259464
PMCPMC10800824
OpenAlexW4390664961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.